Harmony Biosciences Holdings, Inc. HRMY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 76.5%-0.6pp | 77.2%-0.5pp | 77.7%-0.6pp | 78.3%0.0pp | 78.3%+0.3pp | |
| Operating margin | 21.1%-2.9pp | 24%-3.3pp | 27.3%-1.4pp | 28.7%+2.5pp | 26.2%-0.5pp | |
| Net margin | 16.2%-2.1pp | 18.3%-4.2pp | 22.5%-0.9pp | 23.4%+2.9pp | 20.5%+0.1pp | |
| Returns | ||||||
| Return on equity | 17.9%-2.9pp | 20.8%-5.2pp | 25.9%-1.7pp | 27.6%+2.9pp | 24.7%-1.1pp | |
| Return on invested capital | 31.2%-14.4pp | 45.6%-2.7pp | 48.3%+4.3pp | 44%+5.5pp | 38.5%-0.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.6×0.0× | 3.6×-0.2× | 3.8×-0.1× | 3.8×+0.2× | 3.7×+0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Net debt / EBITDA | -2×+0.5× | -2.5×-0.6× | -1.9×-0.4× | -1.5×-0.1× | -1.4×-0.2× | |
| Per Share | ||||||
| Book value per share | $15.49+4.2% | $14.86+4.5% | $14.22+7.5% | $13.23+7.5% | $12.31+8.1% | |
| Valuation | ||||||
| Market capitalization | $1.62B-24.8% | $2.16B+35.9% | $1.59B-13.9% | $1.84B-3.3% | $1.9B-3.0% | |
| Price / earnings | 11.1×-2.5× | 13.6×+5.0× | 8.5×-1.6× | 10.2×-2.3× | 12.5×-1.0× | |
| Price / sales | 1.8×-0.7× | 2.5×+0.6× | 1.9×-0.5× | 2.4×-0.2× | 2.6×-0.2× | |
| Price / book | 1.8×-0.7× | 2.5×+0.6× | 1.9×-0.5× | 2.4×-0.3× | 2.6×-0.3× | |
| EV / EBITDA | 5.6×-1.2× | 6.8×+2.3× | 4.4×-1.5× | 6×-1.3× | 7.3×-0.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Harmony Biosciences Holdings, Inc.'s profit margins?
- Harmony Biosciences Holdings, Inc. (HRMY) runs a 76.5% gross margin and a 21.1% operating margin, with a 16.2% net margin.
- Where do Harmony Biosciences Holdings, Inc.'s ratios come from?
- Every ratio is computed from Harmony Biosciences Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.